-
Media ReleaseNovartis drug Signifor® gains FDA approval as the first medication to treat Cushing's disease, a serious endocrine disorder
-
Media ReleaseNovartis Phase III study shows RLX030 improved symptoms and reduced deaths by one-third in patients with acute heart failure
-
Media ReleaseLeeza Gibbons joins Novartis to improve caregiving experience for millions of Americans through real-world peer advice on AlzheimersDisease.com
-
Media ReleaseNovartis Pharmaceuticals Corporation emprende una campaña de educación de la comunidad hispana de EE. UU. sobre la enfermedad de Alzheimer
-
Media ReleaseNovartis Pharmaceuticals Corporation embarks on Alzheimer’s disease educational effort for the U.S. Hispanic community
-
Media ReleaseFDA Advisory Committee supports use of tobramycin inhalation powder from Novartis for patients with cystic fibrosis
-
Media ReleaseHigher dose of Novartis drug Exelon® Patch approved by FDA for patients with mild to moderate Alzheimer's disease
-
Media ReleaseNPC Statement on Comments Made in Media Coverage of Paycheck Fairness Act
-
Media ReleaseTwo new analyses reinforce consistent efficacy of Novartis therapy Gilenya across wide range of relapsing MS patients
-
Media ReleaseTV host Phil Keoghan and professional women cyclists join Novartis to raise awareness of multiple sclerosis
-
Media ReleaseHigher dose of Novartis drug Exelon® Patch showed statistically significantly less decline in function in Alzheimer’s vs. lower dose
-
Media ReleaseNew extension study data with Novartis drug Gilenya shows patients successfully treated for up to 7 years in relapsing MS